|
Jul 23
|
Nanotechnology in medicine: Who are the leading public companies?
|
|
Jun 26
|
Recent uptick might appease Gilead Sciences, Inc. (NASDAQ:GILD) institutional owners after losing 4.6% over the past year
|
|
Jun 25
|
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
|
|
Jun 24
|
The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine
|
|
Jun 21
|
Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock
|
|
Jun 21
|
US indexes open mixed, pharmaceutical stocks climb: Morning Brief
|
|
Jun 21
|
Gilead sees encouraging results from shot to prevent HIV
|
|
Jun 21
|
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
|
|
Jun 21
|
Defying the Norms: 3 High P/E Stocks With Room to Run
|
|
Jun 21
|
5 Things to Know Before the Stock Market Opens
|
|
Jun 21
|
Strength Seen in Gilead (GILD): Can Its 8.5% Jump Turn into More Strength?
|
|
Jun 8
|
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
|
|
Jun 7
|
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
|
|
Jun 6
|
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
|
|
Jun 6
|
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA
|
|
Jun 6
|
Gilead’s seladelpar shows promise in primary biliary cholangitis trial
|
|
Jun 6
|
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
|
|
Jun 5
|
Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?
|
|
Jun 5
|
Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis
|
|
Jun 5
|
Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks
|